LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

LB Pharmaceuticals (Nasdaq: LBRX) announced an inducement equity award to its new Chief Commercial Officer, Kaya Pai Panandiker, granted on December 10, 2025 under the Nasdaq Listing Rule 5635(c)(4) exception.

Rhea-AI Summary

LB Pharmaceuticals (Nasdaq: LBRX) announced an inducement equity award to its new Chief Commercial Officer, Kaya Pai Panandiker, granted on December 10, 2025 under the Nasdaq Listing Rule 5635(c)(4) exception. The award is an option to purchase 195,000 shares of common stock with a 10-year term and an exercise price of $21.36 per share (closing price on the grant date). The option vests over 4 years: 25% on the first anniversary and the remaining shares in equal monthly installments (1/48th) thereafter, subject to continuous service.

Argus Dec 11 session

-5.29% close to close Open Argus

Details

News Market Reaction – LBRX

In the Dec 11 session, LBRX declined 5.29%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -5.3% in the session following this news. A negative reaction despite this routine i...

Analysis

The stock moved -5.3% in the session following this news. A negative reaction despite this routine inducement grant would fit a pattern where LBRX shares previously moved counter to generally constructive updates. The award grants 195,000 options at $21.36 with multi-year vesting, modestly expanding potential dilution but chiefly serving to align the CCO with shareholders. Given recent history of declines around leadership and index announcements, traders could reassess whether selling pressure reflects positioning rather than the substance of the grant.

Key Figures

Option exercise price: $21.36 per share Option grant size: 195,000 shares Option term: 10 years +1 more

Option exercise price

$21.36 per share

Inducement option grant to CCO on Dec 10, 2025

Option grant size

195,000 shares

Inducement option grant to CCO under Nasdaq Rule 5635(c)(4)

Option term

10 years

Term of CCO inducement stock option

Vesting schedule

4 years; 25% at 1 year, then 1/48 monthly

Vesting terms for CCO inducement option

Historical Context

5 past events · Latest: Dec 09

5 events

1. Dec 09

   Index inclusion news

   24h Move

   -2.3%

   Announcement of addition to Russell 2000 and 3000 indices.

2. Nov 24

   Conference presentation

   24h Move

   +5.3%

   Piper Sandler healthcare conference presentation announcement.

3. Nov 12

   Inducement option grant

   24h Move

   -5.6%

   Inducement equity award to new SVP of Regulatory Affairs.

4. Nov 12

   Executive appointment

   24h Move

   -5.6%

   Appointment of Kaya Pai Panandiker as Chief Commercial Officer.

5. Nov 06

   Conference presentation

   24h Move

   -1.0%

   Stifel healthcare conference presentation announcement.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), inducement grant, equity incentive plan, exercise price

4 terms

nasdaq listing rule 5635(c)(4) regulatory

"pursuant to the “inducement grant” exception provided under Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement grant financial

"pursuant to the “inducement grant” exception provided under Nasdaq Listing Rule 5635(c)(4)"

An inducement grant is a stock-based reward given to a new hire—often options or restricted shares—used as a recruiting “signing bonus” to encourage someone to join a company and stay long enough to add value. Investors care because these grants can dilute existing shareholdings, change executive incentives and increase reported compensation costs, so they signal both management priorities and potential impacts on shareholder value.

equity incentive plan financial

"subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

exercise price financial

"an exercise price per share equal to $21.36, which was the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Dec. 10, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that it has granted to Kaya Pai Panandiker, the new Chief Commercial Officer of LB Pharmaceuticals, an equity award outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity award was granted on December 10, 2025, pursuant to the “inducement grant” exception provided under Nasdaq Listing Rule 5635(c)(4) as an inducement material to Ms. Pai Panandiker entering into employment with LB Pharmaceuticals.

Ms. Pai Panandiker received an option to purchase 195,000 shares of LB Pharmaceuticals’ common stock. The option carries a ten-year term and an exercise price per share equal to $21.36, which was the closing price of LB Pharmaceuticals’ common stock on the date of grant, and vests over 4 years, with 25% of the shares underlying the options vesting on the first anniversary of the grant date and an additional 1/48^th of the shares vesting monthly thereafter, subject to continuous service through the applicable vesting dates.

About LB-102

LB-102 is a Phase 3-ready oral, small molecule and a methylated derivative of amisulpride. In early 2025, LB Pharmaceuticals announced positive data from a four-week placebo-controlled, double-blinded, Phase 2 trial in patients with acute schizophrenia. The Phase 2 trial demonstrated statistically significant benefit versus placebo at all doses studied, a potentially class leading safety profile among D2 antagonists and partial agonists, and positive effects on negative symptoms and cognition. LB-102 is advancing into a Phase 3 clinical trial for acute schizophrenia and a Phase 2 clinical trial for bipolar depression. Additional expansion opportunities for LB-102 could include major depressive disorder (MDD), predominantly negative symptoms of schizophrenia, Alzheimer’s disease psychosis and agitation, as well as bipolar mania and cognitive impairment associated with schizophrenia.

About LB Pharmaceuticals

LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a potentially attractive alternative to branded and generic therapeutics for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.

Contacts
Media: 
Michael Tattory
LifeSci Communications
Mtattory@lifescicomms.com

Investor Relations: 
Joyce Allaire 
LifeSci Advisors 
JAllaire@LifeSciAdvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who received the inducement grant from LB Pharmaceuticals (LBRX) on December 10, 2025?

Kaya Pai Panandiker, the company's new Chief Commercial Officer, received the inducement option grant.

How many shares were included in the LBRX inducement option grant and what is the term?

The option covers 195,000 shares and carries a 10-year term from the December 10, 2025 grant date.

What is the exercise price for the LBRX option granted December 10, 2025?

The exercise price is $21.36 per share, equal to the closing price on the grant date.

What is the vesting schedule for the LB Pharmaceuticals (LBRX) inducement option?

The option vests over 4 years: 25% on the first anniversary and then 1/48th of the total shares monthly thereafter, subject to continuous service.

Under which Nasdaq rule was the LB Pharmaceuticals grant made for LBRX?

The award was made pursuant to the inducement grant exception under Nasdaq Listing Rule 5635(c)(4).

Does the LBRX announcement state any cash compensation or other financial terms for the new CCO?

No; the announcement specifies only the equity option grant, exercise price, term, and vesting schedule.